Navigation Links
Accounting for biological aggregation in heating and imaging of magnetic nanoparticles
Date:9/2/2014

Biological aggregation is a critical, yet often overlooked factor in the medical application of nanoparticles. Here we systematically characterize the effects of aggregation on both radiofrequency heating and magnetic resonance image (MRI) contrast of magnetic iron oxide nanoparticles (IONPs), including detailed analysis of the aggregate morphologies based on quasi-fractal descriptions. While aggregation is shown to produce significant reductions in both heating and MRI contrast, we also present a new method to quantify and correlate these effects for clinical applications, such as cancer hyperthermia, utilizing sweep imaging with Fourier transform (SWIFT) MRI. Therefore, the results of this work not only present new methods to systematically examine a poorly understood area of nanomedicine (not unique to magnetic nanoparticles), but also demonstrate an imaging platform to account for it in the clinic.

Jack Hoopes, Ph.D., D.V.M., of Dartmouth College and Principal Investigator at the Dartmouth Center for Cancer Nanotechnology Excellence (DCCNE) says, "It is now clear that development of a clinically effective magnetic nanoparticle cancer treatment will require nanoparticles that have significant magnetic field-initiated heating potential and the ability to be observed accurately in a non-invasive, real-time manner. Your University of Minnesota MR-SWIFT imaging technology is the first to demonstrate that magnetic nanoparticles can be observed and quantified, with excellent contrast and resolution, at therapeutically meaningful levels using a conventional imaging technology. Equally important is your demonstration that SWIFT MRI can be used to predict the level of therapeutic heating for a specific amount of tumor iron (IONPs) and that IONP aggregation, in the tumor, is critical to understanding heat generation. Our DCCNE looks forward to working with you and your recently developed techniques to enhance our upcoming IONP clinical trials." The DCCNE is attempting to conduct the first in-human clinical trials related to IONP based cancer hyperthermia in the U.S.

On-going work at the University of Minnesota and Dartmouth College plans to expand on the preliminary in vivo studies presented here and demonstrate intra-operative concentration and SAR mapping for IONP treatments that will translate to the clinical setting. This includes opportunities to increase the range of measurable IONP concentrations beyond those already established (up to 3-4 mg Fe/ml) through increased acquisition bandwidth or multi-band-SWIFT. This not only has im-portant implications for cancer hyperthermia applications, but may provide a platform to perform transient, non-invasive biodistribution studies on IONPs. Finally, as the interparticle interactions due to aggregation were determined to be detrimental to the IONPs' heating potential, the authors are also investigating new ways to account for it using SWIFT (as shown here) and controlling it through new coatings which additionally increase the potential for future targeting and drug payload inclusion.


'/>"/>

Contact: Philly Lim
mllim@wspc.com
656-466-5775
World Scientific
Source:Eurekalert  

Related biology technology :

1. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
2. Accounting Firm Rankings: TaxOps Takes Top Small Firm Spot for the Second Consecutive Year
3. SASB Releases Provisional Sustainability Accounting Standards for Health Care Industry, A Key Milestone in Improving Disclosure of Material Non-Financial Information
4. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
5. Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update
6. UMD Researchers Bridge Gap between Microelectronics, Biological Systems
7. Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
8. Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology
9. Collaboration Between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington
10. Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures
11. Researcher studying biological factors of blood glucose variability wins 2013 IDF Europe Prize in Diabetes for Young Researcher
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Accounting for biological aggregation in heating and imaging of magnetic nanoparticles
(Date:2/22/2017)... ... 2017 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), a ... announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s ... commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio and ...
(Date:2/22/2017)... Feb. 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... a study that validated the ability of the Aethlon ... with increased mortality in immune-suppressed sepsis patients and also ... The objective of the study was to validate ... Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) ...
(Date:2/21/2017)... Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... protect and restore the health of patients, intends to report operational ... on Thursday, March 2, 2017, and to host a conference call ... the call is as follows: U.S. (toll free): 1-888-347-5280 ... ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... that Dr. Trevor Heritage has joined its executive team to lead the development ... to provide insights to help improve the diagnosis and treatment of cancer. The ...
Breaking Biology Technology:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):